MREO: Class Action Filed—Act Now to Protect Your Rights!

Lead Plaintiff Deadline: A securities class action lawsuit has been filed on behalf of Mereo BioPharma Group plc (NASDAQ: MREO) investors, with a lead plaintiff deadline of April 6, 2026 (intellectia.ai). The suit alleges that Mereo misled investors about the prospects of its key drug setrusumab in Phase 3 trials, inflating the stock price and causing losses when the truth emerged (intellectia.ai). Below is a deep-dive into Mereo’s fundamentals – including its dividend policy, financial leverage, valuation, and the risks/red flags surrounding the company – to help shareholders understand the situation and protect their rights.

Company Overview 📈

Mereo BioPharma Group plc is a UK-based biopharmaceutical company focused on developing therapeutics for rare diseases (robbinsllp.com). Its pipeline has included: setrusumab (UX143) for osteogenesis imperfecta (brittle bone disease), partnered with Ultragenyx; alvelestat (MPH-966) for alpha-1 antitrypsin deficiency lung disease; and other earlier-stage assets (e.g. etigilimab in oncology, acumapimod for respiratory disease, and leflutrozole for hypogonadism) (www.sec.gov) (www.sec.gov). Mereo has pursued partnerships to fund development – notably a $50 million upfront payment from Ultragenyx in 2021 for setrusumab rights (www.sec.gov) (www.sec.gov), and out-licensing deals for non-core programs like navicixizumab (oncology) and leflutrozole (www.sec.gov) (www.sec.gov). The company’s strategy has been to retain some commercial rights in Europe for rare disease programs while leveraging partners for global development costs (www.sec.gov) (www.sec.gov).

Recent Developments: In late 2025, a major setback hit the company. Ultragenyx’s Phase 3 “ORBIT” and “COSMIC” trials of setrusumab failed to meet their primary endpoints, as neither study showed a statistically significant reduction in annualized fracture rates versus placebo or standard of care (www.biospace.com) (www.biospace.com). (The trials did show improved bone density as a secondary endpoint, but this was not enough to meet the key efficacy goals (www.biospace.com) (www.biospace.com).) Ultragenyx’s CEO expressed “surprise and disappointment” at the outcome, given positive Phase 2 data (www.biospace.com). Mereo’s stock price plunged on this news, as the market reassessed the value of setrusumab and the company’s future prospects. Multiple investor law firms — including Rosen Law, Portnoy, Gross LLP, and others — have since announced investigations or class actions, alleging that Mereo’s executives overstated their confidence in the Phase 3 trials’ expected success while concealing adverse facts (i.e. that the trials were not meeting endpoints) (robbinsllp.com) (robbinsllp.com). Shareholders who bought MREO between June 5, 2023 and Dec 26, 2025 may have paid artificially inflated prices, only to incur losses when the trial results were disclosed (robbinsllp.com). This context sets the stage for evaluating Mereo’s fundamentals and what investors should consider now.

Dividend Policy & Shareholder Yield 💰

Mereo does not pay any dividends and has never declared a cash dividend since its inception (www.sec.gov). As a clinical-stage biotech, the company prioritizes reinvesting capital into R&D and pipeline development over returning cash to shareholders (www.sec.gov). Management has stated it “intends to retain all available funds and any future earnings to fund the development and expansion of its business”, and it does not anticipate paying dividends in the foreseeable future (www.sec.gov). This means MREO’s dividend yield is 0%, and investors should not expect income from this stock. In fact, given the ongoing operating losses (Mereo reported a net loss of £34.2 million in 2022 (www.sec.gov)), there are no profits or cash flows available to distribute. Traditional cash-flow metrics like FFO/AFFO (Funds From Operations) are not applicable here, since Mereo has negative operating cash flow typical of development-stage biotechs (the 2022 operating loss was over £43 million) (www.sec.gov). Shareholders’ returns thus hinge entirely on stock price appreciation driven by successful drug development milestones – a high-risk, high-reward proposition – rather than any steady cash return.

Financial Position and Leverage ⚖️

Cash and Runway: Thanks to prior fundraising and partner payments, Mereo has maintained a cash buffer to support its R&D. As of its last annual filing, management believed existing cash reserves would fund operations “into 2026,” after which additional capital would be needed (www.sec.gov). This guidance (from early 2023) implied roughly 2–3 years of runway at that time. However, with the setback in setrusumab, the timeline to potential revenue has likely been pushed out or derailed, which could strain cash resources sooner. Investors should watch for updates on cash burn and runway in upcoming reports. If the company’s cash-out pace (roughly £25–30 million per year on R&D plus admin (www.sec.gov) (www.sec.gov)) continues, Mereo may need to raise funds or cut costs by late 2025 or 2026 to continue operations. The Ultragenyx alliance had pre-funded OI trials, which helped conserve Mereo’s cash for other programs (www.sec.gov). But with no new milestone payments likely forthcoming after the trial failure, funding pressure is a key concern.

Debt and Maturities: Mereo’s capital structure has minimal traditional debt. The company primarily used convertible loan notes (convertible debt financing) rather than bank loans. Notably, in June 2020 Mereo issued $50.6 million in notes to investors; the majority automatically converted into equity (125 million new ordinary shares) that year, leaving about £6.2 million principal outstanding as of Dec 31, 2022 (www.sec.gov). Those remaining notes are still convertible into shares (with certain 9.99% ownership caps per holder), which means they will likely convert to equity over time rather than require cash repayment (www.sec.gov) (www.sec.gov). Additionally, Mereo entered into a £3.8 million convertible note with Novartis in 2020 (related to an earlier partnership); that note was recently extended to mature in February 2025 after an amendment (www.sec.gov) (www.sec.gov). The Novartis note is also convertible (original conversion price £0.265 per share) and came with warrants (some of which were repriced/extended in the 2023 amendment) (www.sec.gov) (www.sec.gov). Key upcoming maturity: if not converted sooner, the £3.8 M Novartis note will come due in Feb 2025 (www.sec.gov). Mereo would need to repay or refinance it, unless the stock price recovers enough for Novartis to opt for conversion to equity.

Aside from these convertibles, Mereo carries no significant long-term debt. The company even repaid its prior credit facility in full in 2020, eliminating interest-bearing bank debt (www.sec.gov). This means leverage is very low – the remaining debt (~£10 M total) is dwarfed by shareholders’ equity and (historically) by the company’s cash on hand. Interest coverage is not a pressing issue, since interest expense on the convertibles (around £3–4 M annually) is relatively small and was easily serviced out of the cash reserves (though the company has no earnings, it has been paying interest from its balance sheet) (www.sec.gov). In 2022, finance costs actually declined slightly as some notes converted and interest expense dropped (www.sec.gov). The bottom line on leverage: Mereo has funded itself mostly through equity, not debt, which limits insolvency risk. However, the flip side for equity holders is dilution risk – past financings added hundreds of millions of shares (and warrants). Future capital raises will likely also be equity-based (stock or ADS offerings), especially if the share price remains low (traditional debt financing would be hard to obtain without cash flows). Investors should brace for potential dilution if the company raises cash in 2024–2025 to extend its runway.

Valuation and Comparables 📊

Valuing a clinical-stage biotech like Mereo is inherently challenging, as traditional metrics (P/E, EV/EBITDA, etc.) are negative or not meaningful. MREO currently trades primarily on its pipeline potential and remaining cash, rather than current earnings. For instance, Mereo’s net loss in 2022 was £34 million and it had virtually no revenue in 2022 after recognizing one-time license revenue in 2021 (www.sec.gov) (www.sec.gov). With ongoing losses, P/E is not applicable (there are no earnings). Price-to-book (P/B) or enterprise value to cash might be more relevant yardsticks. Given the accumulated deficit, Mereo’s book value largely reflects its cash and intangible R&D assets. If we consider the cash runway into 2026, the market capitalization at any given time can be thought of as the present value of its cash plus the market’s speculative valuation of the drug pipeline.

Before the setrusumab trial results, investors clearly assigned significant value to that program’s success – as evidenced by the stock’s rise during the class period when management expressed optimism. Now, with setrusumab’s primary endpoints missed, a large portion of Mereo’s pipeline value has been impaired. The stock has likely adjusted downward to reflect a scenario where no near-term product approval or big milestone payment is on the horizon. Compared to peers, Mereo might be benchmarked against other small-cap rare disease biotechs with late-stage programs. However, direct comps are few, and each pipeline has unique odds of success. At this point, MREO’s valuation hinges on: the salvageability of setrusumab (can any subgroup or secondary endpoint support a new trial or limited approval?), the prospects for alvelestat (does it advance to Phase 3 with a partner?), and the overall cash buffer. If investors become skeptical that any of Mereo’s drugs will reach market or that dilution will be too severe, the stock could trade close to net cash value (essentially valuing the pipeline at zero). On the other hand, any positive development – e.g. a new partnership or an improved analysis of the OI data – could lift the valuation from distressed levels. In summary, the current pricing of MREO reflects deep uncertainty: the company’s enterprise value has shrunk following the trial failure, and it will remain low unless Mereo rebuilds confidence in its pipeline or becomes a takeover target at a premium.

(Note: Since Mereo is not generating Funds From Operations, metrics like P/FFO or P/AFFO aren’t usable. Investors should instead focus on metrics like cash per share, burn rate, and potential future milestone valuations rather than any dividend yield or FFO multiples.)

Risks, Red Flags, and Investor Safeguards ⚠️

Clinical Trial Failures: The foremost risk is the setback in Mereo’s flagship program. The Phase 3 failure for setrusumab in OI is a major red flag for the company’s future revenue prospects. This drug was a cornerstone of Mereo’s rare-disease strategy and a key value driver. With neither Phase 3 trial meeting its primary endpoint (www.biospace.com) (www.biospace.com), the path to regulatory approval is now uncertain at best. There is a risk that Ultragenyx (Mereo’s development partner) could scale back or discontinue the program, especially since they announced plans to cut expenses after these results (www.biospace.com) (www.biospace.com). For Mereo, that could mean no further milestone payments or royalties from setrusumab – a significant long-term blow. Investors should be aware that Mereo might need to write down the value of setrusumab on its balance sheet if the outlook remains poor. More broadly, this outcome highlights the inherent clinical risk in biotech: even Phase 2 “promising” data did not guarantee Phase 3 success, and Mereo’s pipeline concentration in a few programs amplifies this binary risk.

Misrepresentation Allegations: The class action lawsuit itself underscores a governance and transparency concern. According to the complaint, Mereo’s management projected confidence in setrusumab’s Phase 3 outcomes – for example, suggesting expectation of reduced fracture rates and a successful trial (robbinsllp.com) – while allegedly withholding the fact that the trials were failing to hit endpoints (robbinsllp.com). If these allegations are true, it suggests that investors may have been misled or at least not promptly informed of material negative developments. That is a serious red flag regarding management credibility. Even if the lawsuit’s claims are proven false or dismissed, the mere existence of a securities fraud class action can divert management’s attention and increase costs (legal fees, potential settlement) (www.sec.gov) (www.sec.gov). It can also hurt the company’s ability to raise capital (since new investors may demand a discount due to litigation overhang). Shareholders should monitor the progress of this lawsuit. A win or settlement could possibly bring some compensation, but it might also further strain Mereo’s finances if the company (or its insurers) must pay. Most importantly, trust in management will need rebuilding. Mereo’s board did undergo changes in late 2022 – after an activist investor (Rubric Capital) pushed for a shake-up, four new directors were appointed and four incumbents resigned (www.sec.gov). This was a governance improvement measure at the time. However, the fact that now another controversy has arisen (regarding trial communications) indicates that governance and disclosure practices remain an area of risk. Investors may demand more conservative guidance and better transparency going forward.

Financing & Dilution Risk: As highlighted earlier, Mereo will likely need additional capital by 2026 absent a major turnaround or partnership (www.sec.gov). Given the stock’s depressed price post-trial-news, any equity raise could be highly dilutive. This is a critical risk for current shareholders: raising, say, \$30–50 million could require issuing a very large number of new shares/ADS at low prices, which would significantly dilute existing ownership percentages. In the worst case, if the stock falls into penny-stock territory, access to capital could dry up entirely. The company might then be forced to take drastic steps such as asset sales, a merger, or even wind-down of operations. Convertible securities also pose an overhang – those £6.2 M of notes and large batches of warrants (over 144 million warrants were outstanding as of end-2022) could convert into equity, potentially flooding the float if exercised (www.sec.gov). While conversion would eliminate debt, it would also dilute shareholders further. Mereo’s Nasdaq listing is another vulnerability: in late 2022 the ADS price dipped below \$1, triggering a Nasdaq non-compliance warning (www.sec.gov) (www.sec.gov). The company had to regain compliance by mid-2023 to avoid delisting, likely via either improving the share price or enacting a reverse stock split. If the price sinks again (which is possible after the recent bad news), there’s a risk of Nasdaq delisting. Being delisted to OTC markets would reduce liquidity and could further depress the stock price (www.sec.gov) (www.sec.gov) – a negative spiral to be wary of.

Other Pipeline Risks: Beyond setrusumab, Mereo’s other drug candidates carry their own development risks. Alvelestat showed some positive Phase 2 data in alpha-1 antitrypsin deficiency, but it will require a Phase 3 trial and significant funding. There’s risk that without a partner, Mereo cannot advance alvelestat alone. Etigilimab (an immuno-oncology agent) is early-stage and in a highly competitive field; Mereo has indicated it’s seeking partners for it (www.sec.gov) (www.sec.gov). Essentially, all programs face scientific and regulatory uncertainties – any trial could fail to meet endpoints (as seen with setrusumab), or even if successful, drugs might not gain regulatory approval or commercial traction. Moreover, as a UK company, Mereo faces exchange rate and cross-border regulatory considerations (though these are lesser concerns than the core clinical risks). The company also has contingent value rights (CVRs) outstanding related to its 2019 merger (shareholders of that merger are entitled to a portion of milestones from navicixizumab, etc. (www.sec.gov) (www.sec.gov)). While these don’t affect Mereo’s operations, they do mean part of any big success proceeds might be owed to CVR holders, which is a footnote for valuation.

In sum, Mereo is a high-risk stock at this stage. Its fortunes depend on R&D outcomes that are uncertain, and recent events have tilted those odds in the wrong direction. The red flags – a major clinical failure, subsequent shareholder lawsuits, potential cash crunch, and governance questions – all suggest that investors should exercise caution. Risk-tolerant investors might still see deep value if they believe the pipeline has been unfairly written off, but they must be ready for volatility and possible further disappointments. More conservative investors may choose to stay on the sidelines until there’s clearer evidence of a turnaround or resolution of the legal matters.

Open Questions & What to Watch 🔎

Can Setrusumab Be Salvaged? A critical open question is whether setrusumab has any path forward. The Phase 3 trials missed the primary endpoint, but did hit secondary endpoints (improved bone mineral density) (www.biospace.com). Will regulators consider BMD improvement sufficient for some conditional approval in OI? Or can the trials be extended or re-analyzed to find a subset of patients who benefited (for example, maybe a particular age group or disease severity saw fracture reduction)? Ultragenyx and Mereo will likely “explore the data to gain deeper understanding” (www.biospace.com) – investors should watch for any follow-up analysis or meetings with regulators. If the program is salvaged (even partially), it could revive some of Mereo’s lost value. Conversely, if Ultragenyx walks away entirely, Mereo might regain global rights but then would need to decide if it can fund another trial or not. The outcome here will significantly influence Mereo’s strategy: a continuation vs. a pivot.

What is the Fate of Alvelestat? With setrusumab’s setback, alvelestat (for alpha-1 antitrypsin deficiency lung disease) becomes arguably Mereo’s top unpartnered asset. The company reported encouraging Phase 2 results previously (improvements in certain biomarkers of lung damage), but those were early findings. The question is: will Mereo find a partner or buyer for alvelestat to take it into Phase 3? This indication (AATD) is a rare disease but with some competition (e.g. augmentation therapies exist, and other companies are exploring cures via gene therapy). If management can secure a partnership deal for alvelestat, it could bring in upfront cash and milestone potential, softening the blow from setrusumab. Investors should watch for any partnering announcement or indications that Mereo is prioritizing this program. If no partnership comes, Mereo faces a tough choice: either raise a lot of capital to self-fund costly late-stage trials or shelve the project. The outcome for alvelestat will signal whether Mereo can still create value organically or needs to seek M&A.

How Will the Class Action Resolve? The legal process will play out over many months (if not years), but some near-term events are worth monitoring. The lead plaintiff deadline (April 6, 2026) is when the court will likely appoint a shareholder (or group) to represent the class (intellectia.ai). After that, an initial complaint will be tested – Mereo might file a motion to dismiss the case. Investors should look for any statements from Mereo regarding the allegations. Will the company vehemently deny wrongdoing, or perhaps there were internal disclosures that not all investors caught? Any evidence (emails, statements) that emerges could either reinforce or undermine shareholder confidence in management. If the case survives early motions, discovery could reveal more details about what Mereo’s team knew and when. While this is largely a legal matter, for investors it boils down to: will this lawsuit materially affect the company’s finances or leadership? A hefty settlement could cost millions (though likely covered by insurance to some extent), and if wrongdoing is substantiated, we might see executive departures or further governance changes. Until resolved, the class action is an overhang – but a settlement (without admission of guilt) could also clear it and remove uncertainty. Keeping an eye on press releases from the involved law firms (Rosen, Portnoy, Berger Montague, Gross, etc.) and any SEC filings by Mereo about the litigation is advisable.

Will There Be Strategic Changes? With an activist shareholder (Rubric Capital) already on board since 2022 and the company’s main trial failing, one open question is whether Mereo will pursue strategic alternatives. These could include: merging with or being acquired by another biotech, selling off individual assets, or even a potential privatization. The activist’s involvement hints that all options could be on the table to maximize shareholder value. If the pipeline’s prospects remain dim, the sum-of-parts value (selling drugs to different interested parties) might exceed the stock’s trading value. For example, another rare disease company might value setrusumab or alvelestat assets higher than the market does, especially if they have synergies or different risk appetite. Investors should watch for any signals like retention of an advisory bank or expressions of interest from larger pharma. Another strategic angle: cost cuts – Mereo may significantly downsize its operations to conserve cash (especially since Ultragenyx is covering OI trial costs, Mereo could reduce its own R&D spend). In the Ultragenyx press release, “significant expense reductions” were mentioned (www.biospace.com) – it’s unclear if that refers solely to Ultragenyx’s plans or if Mereo might follow suit. A leaner operation could extend the cash runway but might also slow remaining research.

Nasdaq Compliance and Capital Moves: Lastly, keep an eye on MREO’s stock price relative to Nasdaq requirements. Management took actions before to cure the <$1.00 bid issue (www.sec.gov) (www.sec.gov) – possibly via a reverse split in 2023 (if the price didn’t recover organically). If the price remains very low, another reverse split might be proposed to boost the per-share price. While this doesn’t change underlying value, it can help avoid delisting. On the capital front, any at-the-market (ATM) offering programs or private placements will be telling. If insiders or major holders (like Rubric) inject more capital, that could be a vote of confidence (albeit dilutive). Conversely, if no one is willing to fund the company at a reasonable valuation, that’s a bearish signal.

In summary, Mereo BioPharma faces a pivotal period. Shareholders should stay vigilant about news on the pipeline (setrusumab re-analysis, partnerships on other drugs), developments in the lawsuit, and any financial maneuvers by the company. Given the confluence of scientific, financial, and legal challenges, it’s crucial for investors to do their due diligence and consider their risk tolerance. Those who have incurred losses during the class period might explore joining the class action to seek potential remedies, while those continuing to hold or considering buying must weigh if Mereo’s remaining assets and cash justify the risks ahead.

—

Investor Action: If you purchased MREO ADS between June 5, 2023 and Dec 26, 2025 and have lost money, note that the class action lead plaintiff filing deadline is April 6, 2026 (intellectia.ai). To preserve your rights in the litigation, you may need to contact the litigating law firms or the court before that date. This report is for informational purposes – consider consulting with a legal advisor or shareholder rights attorney if you aim to participate in the lawsuit. Acting within the deadline is important to ensure you don’t lose your right to potential compensation (intellectia.ai). Whether or not you join the class action, maintain awareness of Mereo’s ongoing disclosures and be prepared to make informed decisions to protect your investment interests.

For informational purposes only; not investment advice.